Evidence map›Paper›PMID 35384333›Full record

ArticleClinical and translational medicine2022

HER2/PD1 bispecific antibody in IgG4 subclass with superior anti-tumour activities.

Wendi Chu, Hui Xu, Yanfei Wang, Yongle Xie, Yi-Li Chen, Xiaorong Tan, Chenghao Huang, Guifeng Wang, Qi Wang, Wenxin Luo and 4 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Emerging Immunotherapy Targets in Early Drug Development.International journal of molecular sciences · 2025
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Wendi ChuBiotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Bldg#1, 720 Cai Lun Road, Shanghai, 200126, PR China.ORCID https://orcid.org/0000-0001-7053-4102
Hui XuState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai, 200126, PR China.
Yanfei WangBiotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Bldg#1, 720 Cai Lun Road, Shanghai, 200126, PR China.
Yongle XieState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai, 200126, PR China.
Yi-Li ChenShanghai Mabstone Biotechnology Ltd, Shanghai, PR China.
Xiaorong TanBiotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Bldg#1, 720 Cai Lun Road, Shanghai, 200126, PR China.
Chenghao HuangState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health and School of Life Science, Xiamen University, Xiamen, PR China.
Guifeng WangBiotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Bldg#1, 720 Cai Lun Road, Shanghai, 200126, PR China.ORCID https://orcid.org/0000-0002-0464-4730
Qi WangBiotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Bldg#1, 720 Cai Lun Road, Shanghai, 200126, PR China.
Wenxin LuoState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health and School of Life Science, Xiamen University, Xiamen, PR China.
Ningshao XiaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health and School of Life Science, Xiamen University, Xiamen, PR China.ORCID https://orcid.org/0000-0003-0179-5266
Meiyu GengState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai, 200126, PR China.
Zuoquan XieState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai, 200126, PR China.
Chunhe WangBiotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Bldg#1, 720 Cai Lun Road, Shanghai, 200126, PR China.ORCID https://orcid.org/0000-0002-9598-8968

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, BispecificNeoplasmsHumansImmunoglobulin GAntibodies, BispecificImmunoglobulin G

Identifiers

PMID35384333
PMCPMC8982313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.